Lymphomas: Current Approaches and Future Perspectives towards More Personalized Treatments

Dear Colleagues,

Lymphomas are one of the most prevalent types of cancer and the most frequently occurring of all hematological tumors. Physiologically, the regulation of lymphoid cell differentiation is governed by finely tuned networks of signaling proteins, epigenetic enzymes and transcription factors. The combined action of these different molecules enables the rapid and timely regulation of specific genes during different stages of lymphocyte development. As revealed by large sequencing efforts, many of the proteins involved in these processes are targets of genetic and structural aberrations in lymphomas. Individual aberrations as well as sets of recurrently aberrant genes are characteristic of certain lymphomas and can distinguish specific subtypes of lymphomas with different clinical outcomes and therapeutic responses. Additionally, mechanisms that reduce antitumor immunity including loss of major histocompatibility complex expression, and amplifications and rearrangements of immune checkpoint genes are also frequently observed in lymphomas. Targeted agents against lymphoma-associated proteins and immunotherapies such as antibody–drug conjugates, checkpoint inhibitors and CAR-T cells are currently the focus of efforts towards pharmacological approaches tailored to individual patients’ lymphoma molecular subtype. It is likely that combination or sequential approaches comprising these two classes of agents will lead to more durable responses in more patients than either class alone. This Special Issue of the Journal of Clinical Medicine is focused on current approaches and future perspectives towards more personalized treatments for lymphomas, with the aim of bringing together novel research findings and recent advances in this rapidly developing field.

We warmly invite you to submit an original research paper or review article to this Special Issue.

Dr. Afua Adjeiwaa Mensah
Dr. Patrizia Mondello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.